1. Home
  2. PNTG vs NTLA Comparison

PNTG vs NTLA Comparison

Compare PNTG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PNTG
  • NTLA
  • Stock Information
  • Founded
  • PNTG 2019
  • NTLA 2014
  • Country
  • PNTG United States
  • NTLA United States
  • Employees
  • PNTG N/A
  • NTLA N/A
  • Industry
  • PNTG Medical/Nursing Services
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • PNTG Health Care
  • NTLA Health Care
  • Exchange
  • PNTG Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • PNTG 805.7M
  • NTLA 710.1M
  • IPO Year
  • PNTG N/A
  • NTLA 2016
  • Fundamental
  • Price
  • PNTG $30.22
  • NTLA $8.50
  • Analyst Decision
  • PNTG Buy
  • NTLA Buy
  • Analyst Count
  • PNTG 5
  • NTLA 20
  • Target Price
  • PNTG $36.60
  • NTLA $38.60
  • AVG Volume (30 Days)
  • PNTG 196.1K
  • NTLA 3.3M
  • Earning Date
  • PNTG 05-06-2025
  • NTLA 05-08-2025
  • Dividend Yield
  • PNTG N/A
  • NTLA N/A
  • EPS Growth
  • PNTG 40.99
  • NTLA N/A
  • EPS
  • PNTG 0.76
  • NTLA N/A
  • Revenue
  • PNTG $748,167,000.00
  • NTLA $45,569,000.00
  • Revenue This Year
  • PNTG $23.27
  • NTLA N/A
  • Revenue Next Year
  • PNTG $7.34
  • NTLA N/A
  • P/E Ratio
  • PNTG $39.12
  • NTLA N/A
  • Revenue Growth
  • PNTG 30.04
  • NTLA N/A
  • 52 Week Low
  • PNTG $21.18
  • NTLA $5.90
  • 52 Week High
  • PNTG $37.13
  • NTLA $28.18
  • Technical
  • Relative Strength Index (RSI)
  • PNTG 77.25
  • NTLA 53.64
  • Support Level
  • PNTG $28.78
  • NTLA $7.62
  • Resistance Level
  • PNTG $29.81
  • NTLA $8.89
  • Average True Range (ATR)
  • PNTG 0.99
  • NTLA 0.66
  • MACD
  • PNTG 0.31
  • NTLA 0.03
  • Stochastic Oscillator
  • PNTG 98.95
  • NTLA 62.65

About PNTG The Pennant Group Inc.

Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: